中国抗癌协会神经内分泌肿瘤诊治指南（2022年版）

中国抗癌协会神经内分泌肿瘤专业委员会

doi:10.19401/j.cnki.1007-3639.2022.06.010

您当前的位置：

首页 >

文章列表页 >

中国抗癌协会神经内分泌肿瘤诊治指南（2022年版）

指南与共识 | 更新时间：2025-12-31

- 中国抗癌协会神经内分泌肿瘤诊治指南（2022年版）
- China Anti-Cancer Association guideline for diagnosis and treatment of neuroendocrine neoplasm (2022 edition)
- 中国癌症杂志 2022年32卷第6期页码：545-579
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2022.06.010
  中图分类号： R73
- 收稿：2022-04-15，
  
  修回：2022-05-10，
  
  纸质出版：2022-06-30
- 稿件说明：
移动端阅览
中国抗癌协会神经内分泌肿瘤专业委员会. 中国抗癌协会神经内分泌肿瘤诊治指南（2022年版）[J]. 中国癌症杂志, 2022,32(6):545-579.

of Neuroendocrine Neoplasm of China Anti-Cancer Association Society. China Anti-Cancer Association guideline for diagnosis and treatment of neuroendocrine neoplasm (2022 edition)[J]. China Oncology, 2022, 32(6): 545-579.
中国抗癌协会神经内分泌肿瘤专业委员会. 中国抗癌协会神经内分泌肿瘤诊治指南（2022年版）[J]. 中国癌症杂志, 2022,32(6):545-579. DOI： 10.19401/j.cnki.1007-3639.2022.06.010.

of Neuroendocrine Neoplasm of China Anti-Cancer Association Society. China Anti-Cancer Association guideline for diagnosis and treatment of neuroendocrine neoplasm (2022 edition)[J]. China Oncology, 2022, 32(6): 545-579. DOI： 10.19401/j.cnki.1007-3639.2022.06.010.

摘要

神经内分泌肿瘤（neuroendocrine neoplasm

NEN）是一类起源于肽能神经元和神经内分泌细胞

具有神经内分泌分化并表达神经内分泌标志物的少见肿瘤

可发生于全身各处

以肺及胃肠胰NEN（gastroenteropancreatic neuroendocrine neoplasm

GEP-NEN）最常见。国内外研究数据均提示

NEN的发病率在不断上升。美国流行病学调查结果显示

与其他类型肿瘤相比

NEN的发病率上升趋势更为显著。中国抗癌协会神经内分泌肿瘤专委会在现有循证医学证据基础上

结合已有国内外指南和共识

制订了首版中国抗癌协会神经内分泌肿瘤诊治指南

为临床工作者提供参考。

Abstract

Neuroendocrine neoplasm (NEN) is a kind of rare tumor that originated from peptidergic neurons and neuroendocrine cells

which has neuroendocrine differentiation and expresses neuroendocrine markers. NEN occurs in all parts of the body

especially in lung

stomach

intestine and pancreas. Domestic and international research data suggested that the incidences of NEN were rising. The results of epidemiological investigation showed that compared with other types of tumors

the incidences of NEN increased more significantly. On the basis of existing evidence

combined with domestic and international guidelines and consensus

the Society of Neuroendocrine Neoplasm of China Anti-Cancer Association has formulated its first guideline for diagnosis and treatment of NEN as reference for clinical physicians.

关键词

Keywords

references

DASARI A , SHEN C , HALPERIN D , et al . Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States [J ] . JAMA Oncol , 2017 , 3 ( 10 ): 1335 - 1342 . DOI: 10.1001/jamaoncol.2017.0589 http://doi.org/10.1001/jamaoncol.2017.0589 http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2017.0589 http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2017.0589

FANG C , WANG W , ZHANG Y , et al . Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China [J ] . Chin J Cancer , 2017 , 36 ( 1 ): 51 . DOI: 10.1186/s40880-017-0218-3 http://doi.org/10.1186/s40880-017-0218-3 https://cancercommun.biomedcentral.com/articles/10.1186/s40880-017-0218-3 https://cancercommun.biomedcentral.com/articles/10.1186/s40880-017-0218-3

FAN J H , ZHANG Y Q , SHI S S , et al . A nation-wide retrospective epidemiological study of gastroenteropancreatic neuroendocrine neoplasms in China [J ] . Oncotarget , 2017 , 8 ( 42 ): 71699 - 71708 . DOI: 10.18632/oncotarget.17599 http://doi.org/10.18632/oncotarget.17599 https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.17599 https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.17599

MINNETTI M , GROSSMAN A . Somatic and germline mutations in NETs: implications for their diagnosis and management [J ] . Best Pract Res Clin Endocrinol Metab , 2016 , 30 ( 1 ): 115 - 127 . DOI: 10.1016/j.beem.2015.09.007 http://doi.org/10.1016/j.beem.2015.09.007 https://linkinghub.elsevier.com/retrieve/pii/S1521690X15000962 https://linkinghub.elsevier.com/retrieve/pii/S1521690X15000962

FALCONI M , ERIKSSON B , KALTSAS G , et al . ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors [J ] . Neuroendocrinology , 2016 , 103 ( 2 ): 153 - 171 . DOI: 10.1159/000443171 http://doi.org/10.1159/000443171 https://www.karger.com/Article/FullText/443171 https://www.karger.com/Article/FullText/443171

FAVE G D , O'TOOLE D , SUNDIN A , et al . ENETS consensus guidelines update for gastroduodenal neuroendocrine neoplasms [J ] . Neuroendocrinology , 2016 , 103 ( 2 ): 119 - 124 . DOI: 10.1159/000443168 http://doi.org/10.1159/000443168 https://www.karger.com/Article/FullText/443168 https://www.karger.com/Article/FullText/443168

XU J M , SHEN L , ZHOU Z W , et al . Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study [J ] . Lancet Oncol , 2020 , 21 ( 11 ): 1500 - 1512 . DOI: 10.1016/S1470-2045(20)30496-4 http://doi.org/10.1016/S1470-2045(20)30496-4 https://linkinghub.elsevier.com/retrieve/pii/S1470204520304964 https://linkinghub.elsevier.com/retrieve/pii/S1470204520304964

XU J M , SHEN L , BAI C M , et al . Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study [J ] . Lancet Oncol , 2020 , 21 ( 11 ): 1489 - 1499 . DOI: 10.1016/S1470-2045(20)30493-9 http://doi.org/10.1016/S1470-2045(20)30493-9 https://linkinghub.elsevier.com/retrieve/pii/S1470204520304939 https://linkinghub.elsevier.com/retrieve/pii/S1470204520304939

STROSBERG J , EL-HADDAD G , WOLIN E , et al. Phase 3 trial of 177 Lu-dotatate for midgut neuroendocrine tumors [J ] . N Engl J Med , 2017 , 376 ( 2 ): 125 - 135 . DOI: 10.1056/NEJMoa1607427 http://doi.org/10.1056/NEJMoa1607427 http://www.nejm.org/doi/10.1056/NEJMoa1607427 http://www.nejm.org/doi/10.1056/NEJMoa1607427

CAPLIN M E , PAVEL M , ĆWIKŁA J B , et al . Lanreotide in metastatic enteropancreatic neuroendocrine tumors [J ] . N Engl J Med , 2014 , 371 ( 3 ): 224 - 233 . DOI: 10.1056/NEJMoa1316158 http://doi.org/10.1056/NEJMoa1316158 http://www.nejm.org/doi/10.1056/NEJMoa1316158 http://www.nejm.org/doi/10.1056/NEJMoa1316158

YAO J C , SHAH M H , ITO T , et al . Everolimus for advanced pancreatic neuroendocrine tumors [J ] . N Engl J Med , 2011 , 364 ( 6 ): 514 - 523 . DOI: 10.1056/NEJMoa1009290 http://doi.org/10.1056/NEJMoa1009290 http://www.nejm.org/doi/abs/10.1056/NEJMoa1009290 http://www.nejm.org/doi/abs/10.1056/NEJMoa1009290

RAYMOND E , DAHAN L , RAOUL J L , et al . Sunitinib malate for the treatment of pancreatic neuroendocrine tumors [J ] . N Engl J Med , 2011 , 364 ( 6 ): 501 - 513 . DOI: 10.1056/NEJMoa1003825 http://doi.org/10.1056/NEJMoa1003825 http://www.nejm.org/doi/abs/10.1056/NEJMoa1003825 http://www.nejm.org/doi/abs/10.1056/NEJMoa1003825

FIORE F , DEL PRETE M , FRANCO R , et al . Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors [J ] . Endocrine , 2014 , 47 ( 1 ): 177 - 182 . DOI: 10.1007/s12020-013-0130-9 http://doi.org/10.1007/s12020-013-0130-9 http://link.springer.com/10.1007/s12020-013-0130-9 http://link.springer.com/10.1007/s12020-013-0130-9

LIU Y M , CHEN W C , CUI W , et al . Quantitative pretreatment CT parameters as predictors of tumor response of NET liver metastasis to TAE [J ] . Neuroendocrinology , 2020 , 110 ( 7-8 ): 697 - 704 . DOI: 10.1159/000504257 http://doi.org/10.1159/000504257 https://www.karger.com/Article/FullText/504257 https://www.karger.com/Article/FullText/504257

樊代明,总主编 . 李强 , 刘巍 , 刘红,主编 . 整合肿瘤学-临床卷, 头胸部肿瘤分册 [M ] . 北京 : 科学出版社 , 2021 : 289 .

FAN D M,editor in chief . LI Q , LIU W , LIU LIU H chief editor . Integrated oncology clinical volume, head and chest tumor volume: clinical volume [M ] . Beijing : Science Press , 2021 : 289 .

The current surgical treatment of pancreatic neuroendocrine neoplasms in China: a national wide cross-sectional study [J ] . J Pancreatol , 2019 , 2 : 35 - 42 . DOI: 10.1097/JP9.0000000000000019 http://doi.org/10.1097/JP9.0000000000000019 https://journals.lww.com/02070903-201906000-00002 https://journals.lww.com/02070903-201906000-00002

WU W M , CHEN J , BAI C M , et al . The Chinese guidelines for the diagnosis and treatment of pancreatic neuroendocrine neoplasms (2020) [J ] . Chin J Surg , 2021 , 59 ( 6 ): 401 - 421 .

HALPERIN D M , SHEN C , DASARI A , et al . Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study [J ] . Lancet Oncol , 2017 , 18 ( 4 ): 525 - 534 . DOI: 10.1016/S1470-2045(17)30110-9 http://doi.org/10.1016/S1470-2045(17)30110-9 https://linkinghub.elsevier.com/retrieve/pii/S1470204517301109 https://linkinghub.elsevier.com/retrieve/pii/S1470204517301109

FILOSSO P L , YAO X P , AHMAD U , et al . Outcome of primary neuroendocrine tumors of the thymus: a joint analysis of the International Thymic Malignancy Interest Group and the European Society of Thoracic Surgeons databases [J ] . J Thorac Cardiovasc Surg , 2015 , 149 ( 1 ): 103-109.e2.

MAROTTA V , ZATELLI M C , SCIAMMARELLA C , et al . Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame [J ] . Endocr Relat Cancer , 2018 , 25 ( 1 ): R11-R29.

HOFLAND J , ZANDEE W T , DE HERDER W W . Role of biomarker tests for diagnosis of neuroendocrine tumours [J ] . Nat Rev Endocrinol , 2018 , 14 ( 11 ): 656 - 669 . DOI: 10.1038/s41574-018-0082-5 http://doi.org/10.1038/s41574-018-0082-5 https://doi.org/10.1038/s41574-018-0082-5 https://doi.org/10.1038/s41574-018-0082-5

NOBELS F R , KWEKKEBOOM D J , COOPMANS W , et al . Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones [J ] . J Clin Endocrinol Metab , 1997 , 82 ( 8 ): 2622 - 2628 .

BAUDIN E , GIGLIOTTI A , DUCREUX M , et al . Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours [J ] . Br J Cancer , 1998 , 78 ( 8 ): 1102 - 1107 . DOI: 10.1038/bjc.1998.635 http://doi.org/10.1038/bjc.1998.635 https://doi.org/10.1038/bjc.1998.635 https://doi.org/10.1038/bjc.1998.635

MEIJER W G , KEMA I P , VOLMER M , et al . Discriminating capacity of indole markers in the diagnosis of carcinoid tumors [J ] . Clin Chem , 2000 , 46 ( 10 ): 1588 - 1596 . DOI: 10.1093/clinchem/46.10.1588 http://doi.org/10.1093/clinchem/46.10.1588 https://academic.oup.com/clinchem/article/46/10/1588/5641267 https://academic.oup.com/clinchem/article/46/10/1588/5641267

MODLIN I M , DROZDOV I , KIDD M . The identification of gut neuroendocrine tumor disease by multiple synchronous transcript analysis in blood [J ] . PLoS One , 2013 , 8 ( 5 ): e63364.

MODLIN I M , DROZDOV I , ALAIMO D , et al . A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection [J ] . Endocr Relat Cancer , 2014 , 21 ( 4 ): 615 - 628 . DOI: 10.1530/ERC-14-0190 http://doi.org/10.1530/ERC-14-0190 https://erc.bioscientifica.com/view/journals/erc/21/4/615.xml https://erc.bioscientifica.com/view/journals/erc/21/4/615.xml

LEWIS M A . Hereditary syndromes in neuroendocrine tumors [J ] . Curr Treat Options Oncol , 2020 , 21 ( 6 ): 1 - 8 . DOI: 10.1007/s11864-019-0692-8 http://doi.org/10.1007/s11864-019-0692-8 https://doi.org/10.1007/s11864-019-0692-8 https://doi.org/10.1007/s11864-019-0692-8

EISENHAUER E A , THERASSE P , BOGAERTS J , et al . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) [J ] . Eur J Cancer , 2009 , 45 ( 2 ): 228 - 247 . DOI: 10.1016/j.ejca.2008.10.026 http://doi.org/10.1016/j.ejca.2008.10.026 https://linkinghub.elsevier.com/retrieve/pii/S0959804908008733 https://linkinghub.elsevier.com/retrieve/pii/S0959804908008733

YU R , WACHSMAN A . Imaging of neuroendocrine tumors: indications, interpretations, limits, and pitfalls [J ] . Endocrinol Metab Clin North Am , 2017 , 46 ( 3 ): 795 - 814 . DOI: 10.1016/j.ecl.2017.04.008 http://doi.org/10.1016/j.ecl.2017.04.008 https://linkinghub.elsevier.com/retrieve/pii/S0889852917300385 https://linkinghub.elsevier.com/retrieve/pii/S0889852917300385

PAVEL M , ÖBERG K , FALCONI M , et al . Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J ] . Ann Oncol , 2020 , 31 ( 7 ): 844 - 860 . DOI: 10.1016/j.annonc.2020.03.304 http://doi.org/10.1016/j.annonc.2020.03.304 https://linkinghub.elsevier.com/retrieve/pii/S0923753420363948 https://linkinghub.elsevier.com/retrieve/pii/S0923753420363948

SUNDIN A , ARNOLD R , BAUDIN E , et al . ENETS consensus guidelines for the standards of care in neuroendocrine tumors: radiological, nuclear medicine & hybrid imaging [J ] . Neuroendocrinology , 2017 , 105 ( 3 ): 212 - 244 . DOI: 10.1159/000471879 http://doi.org/10.1159/000471879 https://www.karger.com/Article/FullText/471879 https://www.karger.com/Article/FullText/471879

DAVAR J , CONNOLLY H M , CAPLIN M E , et al . Diagnosing and managing carcinoid heart disease in patients with neuroendocrine tumors: an expert statement [J ] . J Am Coll Cardiol , 2017 , 69 ( 10 ): 1288 - 1304 .

BEIDERWELLEN K , SABET A , LAUENSTEIN T C , et al . Neuroendokrine neoplasien des pankreas [J ] . Der Radiol , 2016 , 56 ( 4 ): 348 - 354 .

BINDERUP T , KNIGGE U , LOFT A , et al . Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123 I-MIBG scintigraphy, and 18 F-FDG PET [J ] . J Nucl Med , 2010 , 51 ( 5 ): 704 - 712 . DOI: 10.2967/jnumed.109.069765 http://doi.org/10.2967/jnumed.109.069765 http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.109.069765 http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.109.069765

RINZIVILLO M , PARTELLI S , PROSPERI D , et al . Clinical usefulness of 18 F-fluorodeoxyglucose positron emission tomography in the diagnostic algorithm of advanced entero-pancreatic neuroendocrine neoplasms [J ] . Oncol , 2018 , 23 ( 2 ): 186 - 192 . DOI: 10.1634/theoncologist.2017-0278 http://doi.org/10.1634/theoncologist.2017-0278 https://academic.oup.com/oncolo/article/23/2/186/6439242 https://academic.oup.com/oncolo/article/23/2/186/6439242

KUIK W J , KEMA I P , BROUWERS A H , et al . In vivo biodistribution of no-carrier-added 6- 18 F-fluoro-3, 4-dihydroxy- L -phenylalanine ( 18 F-DOPA), produced by a new nucleophilic substitution approach, compared with carrier-added 18 F-DOPA, prepared by conventional electrophilic substitution [J ] . J Nucl Med , 2015 , 56 ( 1 ): 106 - 112 . DOI: 10.2967/jnumed.114.145730 http://doi.org/10.2967/jnumed.114.145730 http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.114.145730 http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.114.145730

PICCARDO A , LOPCI E , CONTE M , et al . Comparison of 18 F-dopa PET/CT and 123 I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study [J ] . Eur J Nucl Med Mol Imaging , 2012 , 39 ( 1 ): 57 - 71 . DOI: 10.1007/s00259-011-1938-2 http://doi.org/10.1007/s00259-011-1938-2 http://link.springer.com/10.1007/s00259-011-1938-2 http://link.springer.com/10.1007/s00259-011-1938-2

CARIDEO L , PROSPERI D , PANZUTO F , et al . Role of combined[ 68 Ga ] Ga-DOTA-SST analogues and[ 18 F ] FDG PET/CT in the management of GEP-NENs: a systematic review [J ] . J Clin Med , 2019 , 8 ( 7 ): 1032 . DOI: 10.3390/jcm8071032 http://doi.org/10.3390/jcm8071032 https://www.mdpi.com/2077-0383/8/7/1032 https://www.mdpi.com/2077-0383/8/7/1032

MARZOLA M C , CHONDROGIANNIS S , GRASSETTO G , et al . 18 F-DOPA PET/CT in the evaluation of hereditary SDH-deficiency paraganglioma-pheochromocytoma syndromes [J ] . Clin Nucl Med , 2014 , 39 ( 1 ): e53-e58 .

PAUWELS E , CLEEREN F , BORMANS G , et al . Somatostatin receptor PET ligands-the next generation for clinical practice [J ] . Am J Nucl Med Mol Imaging , 2018 , 8 ( 5 ): 311 - 331 .

PUTZER D , GABRIEL M , KENDLER D , et al . Comparison of 68 Ga-DOTA-Tyr(3)-octreo-tide and 18 F-fluoro- L -dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients [J ] . Q J Nucl Med Mol Imaging , 2010 , 54 ( 1 ): 68 - 75 .

GAINS J E , ALDRIDGE M D , MATTOLI M V , et al . 68 Ga-DOTATATE and 123 I-mIBG as imaging biomarkers of disease localisation in metastatic neuroblastoma: implications for molecular radiotherapy [J ] . Nucl Med Commun , 2020 , 41 ( 11 ): 1169 - 1177 . DOI: 10.1097/MNM.0000000000001265 http://doi.org/10.1097/MNM.0000000000001265 https://journals.lww.com/10.1097/MNM.0000000000001265 https://journals.lww.com/10.1097/MNM.0000000000001265

TELLI T , LAY ERGÜN E , VOLKAN SALANCI B , et al . The complementary role of 68 Ga-DOTATATE PET/CT in neuroblastoma [J ] . Clin Nucl Med , 2020 , 45 ( 4 ): 326 - 329 . DOI: 10.1097/RLU.0000000000002961 http://doi.org/10.1097/RLU.0000000000002961 https://journals.lww.com/10.1097/RLU.0000000000002961 https://journals.lww.com/10.1097/RLU.0000000000002961

TORUN N . 68 Ga-DOTA-TATE in neuroblastoma with marrow involvement [J ] . Clin Nucl Med , 2019 , 44 ( 6 ): 467 - 468 . DOI: 10.1097/RLU.0000000000002539 http://doi.org/10.1097/RLU.0000000000002539 https://journals.lww.com/00003072-201906000-00008 https://journals.lww.com/00003072-201906000-00008

KIM Y I , YOO C , OH S J , et al . Tumour-to-liver ratio determined by[ 68 Ga ] Ga-DOTA-TOC PET/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumours [J ] . EJNMMI Res , 2020 , 10 ( 1 ): 63 . DOI: 10.1186/s13550-020-00651-z http://doi.org/10.1186/s13550-020-00651-z https://doi.org/10.1186/s13550-020-00651-z https://doi.org/10.1186/s13550-020-00651-z

LIU B N , ZHANG Z Z , WANG H , et al . Preclinical evaluation of a dual sstr2 and integrin & #x003b1; v & #x003b2; 3 -targeted heterodimer[ 68 Ga ] -NOTA-3PEG4-TATE-RGD [J ] . Bioorg Med Chem , 2019 , 27 ( 21 ): 115094 . DOI: 10.1016/j.bmc.2019.115094 http://doi.org/10.1016/j.bmc.2019.115094 https://linkinghub.elsevier.com/retrieve/pii/S0968089619309125 https://linkinghub.elsevier.com/retrieve/pii/S0968089619309125

LUO Y P , PAN Q Q , YAO S B , et al . Glucagon-like peptide-1 receptor PET/CT with 68 Ga-NOTA-exendin-4 for detecting localized insulinoma: a prospective cohort study [J ] . J Nucl Med , 2016 , 57 ( 5 ): 715 - 720 . DOI: 10.2967/jnumed.115.167445 http://doi.org/10.2967/jnumed.115.167445 http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.115.167445 http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.115.167445

HÖRSCH D , SCHMID K W , ANLAUF M , et al . Neuroendocrine tumors of the bronchopulmonary system (typical and atypical carcinoid tumors): current strategies in diagnosis and treatment. Conclusions of an expert meeting February 2011 in Weimar, Germany [J ] . Oncol Res Treat , 2014, 37 ( 5 ): 266 - 276 . DOI: 10.1159/000362430 http://doi.org/10.1159/000362430 https://www.karger.com/Article/FullText/362430 https://www.karger.com/Article/FullText/362430

CAPLIN M E , BAUDIN E , FEROLLA P , et al . Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids [J ] . Ann Oncol , 2015 , 26 ( 8 ): 1604 - 1620 . DOI: 10.1093/annonc/mdv041 http://doi.org/10.1093/annonc/mdv041 https://linkinghub.elsevier.com/retrieve/pii/S0923753419318319 https://linkinghub.elsevier.com/retrieve/pii/S0923753419318319

O''TOOLE D , PALAZZO L . Endoscopy and endoscopic ultrasound in assessing and managing neuroendocrine neoplasms [M ] // Neuroendocrine tumors : a multidisciplinary approach . S. Karger AG : 88 - 103 .

CHEN L H , GUO Y , ZHANG Y X , et al . Development of a novel scoring system based on endoscopic appearance for management of rectal neuroendocrine tumors [J ] . Endoscopy , 2021 , 53 ( 7 ): 702 - 709 . DOI: 10.1055/a-1274-0161 http://doi.org/10.1055/a-1274-0161 http://www.thieme-connect.de/DOI/DOI?10.1055/a-1274-0161 http://www.thieme-connect.de/DOI/DOI?10.1055/a-1274-0161

RAMAGE J K , DE HERDER W W , DELLE FAVE G , et al . ENETS consensus guidelines update for colorectal neuroendocrine neoplasms [J ] . Neuroendocrinology , 2016 , 103 ( 2 ): 139 - 143 . DOI: 10.1159/000443166 http://doi.org/10.1159/000443166 https://www.karger.com/Article/FullText/443166 https://www.karger.com/Article/FullText/443166

KHASHAB M A , YONG E , LENNON A M , et al . EUS is still superior to multidetector computerized tomography for detection of pancreatic neuroendocrine tumors [J ] . Gastrointest Endosc , 2011 , 73 ( 4 ): 691 - 696 . DOI: 10.1016/j.gie.2010.08.030 http://doi.org/10.1016/j.gie.2010.08.030 https://linkinghub.elsevier.com/retrieve/pii/S0016510710020547 https://linkinghub.elsevier.com/retrieve/pii/S0016510710020547

DI LEO M , POLIANI L , RAHAL D , et al . Pancreatic neuroendocrine tumours: the role of endoscopic ultrasound biopsy in diagnosis and grading based on the WHO 2017 classification [J ] . Dig Dis , 2019, 37 ( 4 ): 325 - 333 . DOI: 10.1159/000499172 http://doi.org/10.1159/000499172 https://www.karger.com/Article/FullText/499172 https://www.karger.com/Article/FullText/499172

COSTA R D D , KEMP R , SANTOS J S D , et al . The role of conventional echoendoscopy (EUS) in therapeutic decisions in patients with neuroendocrine gastro-intestinal tumors [J ] . Brazilian Archiv Digest Surg , 2020 , 33 ( 2 ): e1512.

PELLICANO R , FAGOONEE S , ALTRUDA F , et al . Endoscopic imaging in the management of gastroenteropancreatic neuroendocrine tumors [J ] . Minerva Endocrinologica , 2016 , 41 ( 4 ): 490 - 8 .

PATEL K K , KIM M K . Neuroendocrine tumors of the pancreas: endoscopic diagnosis [J ] . Curr Opin Gastroenterol , 2008 , 24 ( 5 ): 638 - 642 . DOI: 10.1097/MOG.0b013e32830bf7fb http://doi.org/10.1097/MOG.0b013e32830bf7fb http://journals.lww.com/00001574-200809000-00014 http://journals.lww.com/00001574-200809000-00014

RUSTAGI T , FARRELL J J . Endoscopic diagnosis and treatment of pancreatic neuroendocrine tumors [J ] . J Clin Gastroenterol , 2014 , 48 ( 10 ): 837 - 844 . DOI: 10.1097/MCG.0000000000000152 http://doi.org/10.1097/MCG.0000000000000152 https://journals.lww.com/00004836-201411000-00008 https://journals.lww.com/00004836-201411000-00008

PULI S R , KALVA N , BECHTOLD M L , et al . Diagnostic accuracy of endoscopic ultrasound in pancreatic neuroendocrine tumors: a systematic review and meta analysis [J ] . World J Gastroenterol , 2013 , 19 ( 23 ): 3678 - 3684 . DOI: 10.3748/wjg.v19.i23.3678 http://doi.org/10.3748/wjg.v19.i23.3678 http://www.wjgnet.com/1007-9327/full/v19/i23/3678.htm http://www.wjgnet.com/1007-9327/full/v19/i23/3678.htm

KOS-KUDŁA B , BOLANOWSKI M , HANDKIEWICZ-JUNAK D , et al . Diagnostic and therapeutic guidelines for gastrointestinal neuroendocrine tumors (recommended by the Polish Network of Neuroendocrine Tumors) [J ] . Endokrynol Pol , 2008 , 59 ( 1 ): 41 - 56 .

KIM M K . Endoscopic ultrasound in gastroenteropancreatic neuroendocrine tumors [J ] . Gut Liver , 2012 , 6 ( 4 ): 405 - 410 . DOI: 10.5009/gnl.2012.6.4.405 http://doi.org/10.5009/gnl.2012.6.4.405 http://www.gutnliver.org/journal/DOIx.php?id=10.5009/gnl.2012.6.4.405 http://www.gutnliver.org/journal/DOIx.php?id=10.5009/gnl.2012.6.4.405

VAN ASSELT S J , BROUWERS A H , et al .VAN DULLEMEN H M, EUS is superior for detection of pancreatic lesions compared with standard imaging in patients with multiple endocrine neoplasia type 1 [J ] . Gastrointest Endosc , 2015 , 81 ( 1 ): 159-167.e2.

WHO CLASSIFICATION OF TUMOURS EDITORIAL BOARD . WHO classification of tumours of digestive system [M ] . Lyon : IARC Press , 2019 .

滕晓东 , 李君 , 来茂德 . 肿瘤病理诊断规范(胃肠胰神经内分泌肿瘤) [J ] . 中华病理学杂志 , 2017 , 46 ( 2 ): 76 - 78 .

TENG X D , LI J , LAI M D . Criteria for pathological diagnosis of tumors (gastrointestinal pancreatic neuroendocrine tumors) [J ] . Chin J Pathol , 2017 , 46 ( 2 ): 76 - 78 .

中国胃肠胰神经内分泌肿瘤病理诊断共识专家组 . 中国胃肠胰神经内分泌肿瘤病理诊断共识(2013版) [J ] . 中华病理学杂志 , 2013 , 42 ( 10 ): 691 - 694 .

Consensus Expert Group on Pathological Diagnosis of Gastrointestinal and Pancreatic Neuroendocrine Tumors in China. Consensus on pathological diagnosis of gastrointestinal and pancreatic neuroendocrine tumors in China 2013 edition [J ] . Chin J Pathol , 2013 , 42 ( 10 ): 691 - 694 .

中华医学会病理学分会消化疾病学组 , 年中国胃肠胰神经内分泌肿瘤病理诊断共识专家组 . 中国胃肠胰神经内分泌肿瘤病理诊断共识(2020版) [J ] . 中华病理学杂志 , 2021 , 50 ( 1 ): 14 - 20 .

Digestive diseases group, pathological branch , Chinese Medical Association, consensus expert group on pathological diagnosis of gastrointestinal and pancreatic neuroendocrine tumors in China . Chinese consensus on the pathological diagnosis of gastrointestinal and pancreatic neuroendocrine neoplasms(2020 edition) [J ] . Chin J Pathol , 2021 , 50 ( 1 ): 14 - 20 .

中华医学会消化病学分会胃肠激素与神经内分泌肿瘤学组 . 胃肠胰神经内分泌肿瘤诊治专家共识(2020•广州) [J ] . 中华消化杂志 , 2021 , 41 ( 2 ): 76 - 87 .

Gastrointestinal Hormones and Neuroendocrine Oncology Group, Digestive Branch, Chinese Medical Association. Expert consensus on diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasm (2020, Guangzhou) [J ] . Chin J Dig , 2021, 41 ( 2 ): 76 - 87 .

WHO CLASSIFICATION OF TUMOURS EDITORIAL BOARD . WHO classification of tumours of thoracic tumours [M ] . Lyon : IARC Press , 2021 . (WHO classification of tumours series , 5th ed.

RINDI G , KLIMSTRA D S , ABEDI-ARDEKANI B , et al . A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal [J ] . Mod Pathol , 2018 , 31 ( 12 ): 1770 - 1786 . DOI: 10.1038/s41379-018-0110-y http://doi.org/10.1038/s41379-018-0110-y https://doi.org/10.1038/s41379-018-0110-y https://doi.org/10.1038/s41379-018-0110-y

TRAVIS W D , BRAMBILLA E , BURKE A P , et al . WHO classification of tumours of the lung, pleura, thymus and heart [M ] . Lyon (France) : International Agency for Research on Cancer , 2015 .WHO classification of tumours series, 4th ed, vol.7.

TRAVIS W D , BRAMBILLA E , MÜLLER-HERMELINK H K , et al. editors . Pathology and genetics of tumours of the lung, pleura, thymus and heart [M ] . Lyon (France) : International Agency for Research on Cancer , 2004 . WHO classification of tumours serie s, 3rd ed , vol.10 .

AJCC Cancer Staging Manual . 8th edition , New York , NY , Springer .

陈洛海 , 周志伟 , 陈洁 . 美国癌症联合委员会(AJCC)第8版胃肠胰神经内分泌肿瘤分期解读及评价 [J ] . 中华胃肠外科杂志 , 2017 , 20 ( 9 ): 972 - 976 .

CHEN L H , ZHOU Z W , CHEN J . American Joint Committee on cancer (AJCC), 8th Edition, interpretation and evaluation of staging of gastrointestinal and pancreatic neuroendocrine tumors [J ] . Chin J Gastrointestinal Surg , 2017 , 20 ( 9 ): 972 - 976 .

BASUROY R , SRIRAJASKANTHAN R , PRACHALIAS A , et al . Review article: the investigation and management of gastric neuroendocrine tumours [J ] . Aliment Pharmacol Ther , 2014 , 39 ( 10 ): 1071 - 1084 . DOI: 10.1111/apt.12698 http://doi.org/10.1111/apt.12698 https://onlinelibrary.wiley.com/doi/10.1111/apt.12698 https://onlinelibrary.wiley.com/doi/10.1111/apt.12698

MAIONE F , CHINI A , MILONE M , et al . Diagnosis and management of rectal neuroendocrine tumors (NETs) [J ] . Diagnostics , 2021 , 11 ( 5 ): 771 . DOI: 10.3390/diagnostics11050771 http://doi.org/10.3390/diagnostics11050771 https://www.mdpi.com/2075-4418/11/5/771 https://www.mdpi.com/2075-4418/11/5/771

CROSBY D A , DONOHOE C L , FITZGERALD L , et al . Gastric neuroendocrinetumours [J ] . Dig Surg , 2012 , 29 ( 4 ): 331 - 348 . DOI: 10.1159/000342988 http://doi.org/10.1159/000342988 https://www.karger.com/Article/FullText/342988 https://www.karger.com/Article/FullText/342988

THOMAS D , TSOLAKIS A V , GROZINSKY-GLASBERG S , et al . Long-term follow-up of a large series of patients with type 1 gastric carcinoid tumors: data from a multicenter study [J ] . Eur J Endocrinol , 2013 , 168 ( 2 ): 185 - 193 . DOI: 10.1530/EJE-12-0836 http://doi.org/10.1530/EJE-12-0836 https://eje.bioscientifica.com/view/journals/eje/168/2/185.xml https://eje.bioscientifica.com/view/journals/eje/168/2/185.xml

SHAH M H , GOLDNER W S , BENSON A B , et al . Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology [J ] . J Natl Compr Canc Netw , 2021 , 19 ( 7 ): 839 - 868 . DOI: 10.6004/jnccn.2021.0032 http://doi.org/10.6004/jnccn.2021.0032 https://jnccn.org/view/journals/jnccn/19/7/article-p839.xml https://jnccn.org/view/journals/jnccn/19/7/article-p839.xml

GROZINSKY-GLASBERG S , ALEXANDRAKI K I , ANGELOUSI A , et al . Gastric carcinoids [J ] . Endocrinol Metab Clin North Am , 2018 , 47 ( 3 ): 645 - 660 . DOI: 10.1016/j.ecl.2018.04.013 http://doi.org/10.1016/j.ecl.2018.04.013 https://linkinghub.elsevier.com/retrieve/pii/S0889852918305255 https://linkinghub.elsevier.com/retrieve/pii/S0889852918305255

KIM G H , KIM J I , JEON S W , et al . Endoscopic resection for duodenal carcinoid tumors: a multicenter, retrospective study [J ] . J Gastroenterol Hepatol , 2014 , 29 ( 2 ): 318 - 324 . DOI: 10.1111/jgh.12390 http://doi.org/10.1111/jgh.12390 https://onlinelibrary.wiley.com/doi/10.1111/jgh.12390 https://onlinelibrary.wiley.com/doi/10.1111/jgh.12390

MATSUMOTO S , MIYATANI H , YOSHIDA Y . Future directions of duodenal endoscopic submucosal dissection [J ] . World J Gastrointest Endosc , 2015 , 7 ( 4 ): 389 - 395 . DOI: 10.4253/wjge.v7.i4.389 http://doi.org/10.4253/wjge.v7.i4.389 http://www.wjgnet.com/1948-5190/full/v7/i4/389.htm http://www.wjgnet.com/1948-5190/full/v7/i4/389.htm

HOTEYA S , KAISE M , IIZUKA T , et al . Delayed bleeding after endoscopic submucosal dissection for non-ampullary superficial duodenal neoplasias might be prevented by prophylactic endoscopic closure: analysis of risk factors [J ] . Dig Endosc , 2015 , 27 ( 3 ): 323 - 330 . DOI: 10.1111/den.12377 http://doi.org/10.1111/den.12377 https://onlinelibrary.wiley.com/doi/10.1111/den.12377 https://onlinelibrary.wiley.com/doi/10.1111/den.12377

MATSUMOTO S , MIYATANI H , YOSHIDA Y , et al . Duodenal carcinoid tumors: 5 cases treated by endoscopic submucosal dissection [J ] . Gastrointest Endosc , 2011 , 74 ( 5 ): 1152 - 1156 . DOI: 10.1016/j.gie.2011.07.029 http://doi.org/10.1016/j.gie.2011.07.029 https://linkinghub.elsevier.com/retrieve/pii/S0016510711019699 https://linkinghub.elsevier.com/retrieve/pii/S0016510711019699

MORI H , SHINTARO F , KOBARA H , et al . Successful closing of duodenal ulcer after endoscopic submucosal dissection with over-the-scope clip to prevent delayed perforation [J ] . Dig Endosc , 2013 , 25 ( 4 ): 459 - 461 . DOI: 10.1111/j.1443-1661.2012.01363.x http://doi.org/10.1111/j.1443-1661.2012.01363.x https://onlinelibrary.wiley.com/doi/10.1111/j.1443-1661.2012.01363.x https://onlinelibrary.wiley.com/doi/10.1111/j.1443-1661.2012.01363.x

TAKIMOTO K , IMAI Y , MATSUYAMA K . Endoscopic tissue shielding method with polyglycolic acid sheets and fibrin glue to prevent delayed perforation after duodenal endoscopic submucosal dissection [J ] . Dig Endosc , 2014 , 26 ( Suppl 2 ): 46 - 49 . DOI: 10.1111/den.12280 http://doi.org/10.1111/den.12280 https://onlinelibrary.wiley.com/doi/10.1111/den.12280 https://onlinelibrary.wiley.com/doi/10.1111/den.12280

MAKHLOUF H R , BURKE A P , SOBIN L H . Carcinoid tumors of the ampulla of Vater: a comparison with duodenal carcinoid tumors [J ] . Cancer , 1999 , 85 ( 6 ): 1241 - 1249 . DOI: 10.1002/(SICI)1097-0142(19990315)85:6 < 1241::AID-CNCR5 > 3.0.CO;2-4 http://doi.org/10.1002/(SICI)1097-0142(19990315)85:6 < 1241::AID-CNCR5 > 3.0.CO;2-4 https://onlinelibrary.wiley.com/doi/10.1002/(SICI)1097-0142(19990315)85:6 < 1241::AID-CNCR5 > 3.0.CO;2-4 https://onlinelibrary.wiley.com/doi/10.1002/(SICI)1097-0142(19990315)85:6 < 1241::AID-CNCR5 > 3.0.CO;2-4

陈洛海 , 陈洁 , 周志伟 . 胃肠道神经内分泌肿瘤治疗最新指南解读 [J ] . 中华胃肠外科杂志 , 2016 , 19 ( 11 ): 1201 - 1204 .

CHEN L H , CHEN J , ZHOU Z W . Interpretation of the latest guidelines in the treatment of gastrointestinal neuroendocrine neoplasms [J ] . Chin J Gastrointest Surg , 2016 ( 11 ): 1201 - 1204 .

CHEUNG D Y , CHOI S K , KIM H K , et al . Circumferential submucosal incision prior to endoscopic mucosal resection provides comparable clinical outcomes to submucosal dissection for well-differentiated neuroendocrine tumors of the rectum [J ] . Surg Endosc , 2015 , 29 ( 6 ): 1500 - 1505 . DOI: 10.1007/s00464-014-3831-0 http://doi.org/10.1007/s00464-014-3831-0 http://link.springer.com/10.1007/s00464-014-3831-0 http://link.springer.com/10.1007/s00464-014-3831-0

ZHONG D D , SHAO L M , CAI J T . Endoscopic mucosal resection vs endoscopic submucosal dissection for rectal carcinoid tumours: a systematic review and meta-analysis [J ] . Colorectal Dis , 2013 , 15 ( 3 ): 283 - 291 . DOI: 10.1111/codi.12069 http://doi.org/10.1111/codi.12069 https://onlinelibrary.wiley.com/doi/10.1111/codi.12069 https://onlinelibrary.wiley.com/doi/10.1111/codi.12069

CHOI C W , KANG D H , KIM H W , et al . Comparison of endoscopic resection therapies for rectal carcinoid tumor: endoscopic submucosal dissection versus endoscopic mucosal resection using band ligation [J ] . J Clin Gastroenterol , 2013 , 47 ( 5 ): 432 - 436 . DOI: 10.1097/MCG.0b013e31826faf2b http://doi.org/10.1097/MCG.0b013e31826faf2b https://journals.lww.com/00004836-201305000-00016 https://journals.lww.com/00004836-201305000-00016

刘雪梅 , 庹必光 . 胃肠神经内分泌肿瘤的内镜诊断与治疗 [J ] . 中华胃肠外科杂志 , 2021 , 24 ( 10 ): 854 - 860 .

LIU X M , TUO B G . Endoscopic diagnosis and treatment of gastrointestinal neuroendocrine tumors [J ] . Chin J Gastrointest Surg , 2021 , 24 ( 10 ): 854 - 860 .

PARTELLI S , CIROCCHI R , CRIPPA S , et al . Systematic review of active surveillance versus surgical management of asymptomatic small non-functioning pancreatic neuroendocrine neoplasms [J ] . Br J Surg , 2017 , 104 ( 1 ): 34 - 41 . DOI: 10.1002/bjs.10312 http://doi.org/10.1002/bjs.10312 https://academic.oup.com/bjs/article/104/1/34-41/6122923 https://academic.oup.com/bjs/article/104/1/34-41/6122923

KUO E J , SALEM R R . Population-level analysis of pancreatic neuroendocrine tumors 2 cm or less in size [J ] . Ann Surg Oncol , 2013 , 20 ( 9 ): 2815 - 2821 . DOI: 10.1245/s10434-013-3005-7 http://doi.org/10.1245/s10434-013-3005-7 http://link.springer.com/10.1245/s10434-013-3005-7 http://link.springer.com/10.1245/s10434-013-3005-7

ZHANG X F , XUE F , DONG D H , et al . New nodal staging for primary pancreatic neuroendocrine tumors: a multi-institutional and national data analysis [J ] . Ann Surg , 2021 , 274 ( 1 ): e28-e35.

SCHURR P G , STRATE T , RESE K , et al . Aggressive surgery improves long-term survival in neuroendocrine pancreatic tumors: an institutional experience [J ] . Ann Surg , 2007 , 245 ( 2 ): 273 - 281 . DOI: 10.1097/01.sla.0000232556.24258.68 http://doi.org/10.1097/01.sla.0000232556.24258.68 http://journals.lww.com/00000658-200702000-00017 http://journals.lww.com/00000658-200702000-00017

JIN K Z , XU J , CHEN J , et al . Surgical management for non-functional pancreatic neuroendocrine neoplasms with synchronous liver metastasis: a consensus from the Chinese Study Group for Neuroendocrine Tumors (CSNET) [J ] . Int J Oncol , 2016 , 49 ( 5 ): 1991 - 2000 . DOI: 10.3892/ijo.2016.3711 http://doi.org/10.3892/ijo.2016.3711 https://www.spandidos-publications.com/10.3892/ijo.2016.3711 https://www.spandidos-publications.com/10.3892/ijo.2016.3711

BERTANI E , FAZIO N , BOTTERI E , et al . Resection of the primary pancreatic neuroendocrine tumor in patients with unresectable liver metastases: possible indications for a multimodal approach [J ] . Surgery , 2014 , 155 ( 4 ): 607 - 614 . DOI: 10.1016/j.surg.2013.12.024 http://doi.org/10.1016/j.surg.2013.12.024 https://linkinghub.elsevier.com/retrieve/pii/S0039606013006430 https://linkinghub.elsevier.com/retrieve/pii/S0039606013006430

DE JONG M C , FARNELL M B , SCLABAS G , et al . Liver-directed therapy for hepatic metastases in patients undergoing pancreaticoduodenectomy: a dual-center analysis [J ] . Ann Surg , 2010 , 252 ( 1 ): 142 - 148 . DOI: 10.1097/SLA.0b013e3181dbb7a7 http://doi.org/10.1097/SLA.0b013e3181dbb7a7 https://journals.lww.com/00000658-201007000-00023 https://journals.lww.com/00000658-201007000-00023

OBERG K , KVOLS L , CAPLIN M , et al . Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system [J ] . Ann Oncol , 2004 , 15 ( 6 ): 966 - 973 . DOI: 10.1093/annonc/mdh216 http://doi.org/10.1093/annonc/mdh216 https://linkinghub.elsevier.com/retrieve/pii/S0923753419618387 https://linkinghub.elsevier.com/retrieve/pii/S0923753419618387

HAN X , LOU W H . Concomitant pancreatic neuroendocrine tumors in hereditary tumor syndromes: who, when and how to operate? [J ] . J Pancreatol , 2019 , 2 ( 2 ): 48 - 53 . DOI: 10.1097/JP9.0000000000000016 http://doi.org/10.1097/JP9.0000000000000016 https://journals.lww.com/02070903-201906000-00004 https://journals.lww.com/02070903-201906000-00004

RAZ D J , NELSON R A , GRANNIS F W , et al . Natural history of typical pulmonary carcinoid tumors: a comparison of nonsurgical and surgical treatment [J ] . Chest , 2015 , 147 ( 4 ): 1111 - 1117 . DOI: 10.1378/chest.14-1960 http://doi.org/10.1378/chest.14-1960 https://linkinghub.elsevier.com/retrieve/pii/S0012369215389613 https://linkinghub.elsevier.com/retrieve/pii/S0012369215389613

KURUL I C , TOPÇU S , TAŞTEPE I , et al . Surgery in bronchial carcinoids: experience with 83 patients [J ] . Eur J Cardiothorac Surg , 2002 , 21 ( 5 ): 883 - 887 . DOI: 10.1016/S1010-7940(02)00089-1 http://doi.org/10.1016/S1010-7940(02)00089-1 https://academic.oup.com/ejcts/article-lookup/doi/10.1016/S1010-7940(02)00089-1 https://academic.oup.com/ejcts/article-lookup/doi/10.1016/S1010-7940(02)00089-1

DIVISI D , CRISCI R . Carcinoid tumors of the lung and multimodal therapy [J ] . Thorac Cardiovasc Surg , 2005 , 53 ( 3 ): 168 - 172 . DOI: 10.1055/s-2005-837539 http://doi.org/10.1055/s-2005-837539 http://www.thieme-connect.de/DOI/DOI?10.1055/s-2005-837539 http://www.thieme-connect.de/DOI/DOI?10.1055/s-2005-837539

PHAN A T , OBERG K , CHOI J , et al . NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus) [J ] . Pancreas , 2010 , 39 ( 6 ): 784 - 798 . DOI: 10.1097/MPA.0b013e3181ec1380 http://doi.org/10.1097/MPA.0b013e3181ec1380 https://journals.lww.com/00006676-201008000-00008 https://journals.lww.com/00006676-201008000-00008

HUANG Y W , YANG X D , LU T , et al . Assessment of the prognostic factors in patients with pulmonary carcinoid tumor: a population-based study [J ] . Cancer Med , 2018 , 7 ( 6 ): 2434 - 2441 . DOI: 10.1002/cam4.1515 http://doi.org/10.1002/cam4.1515 https://onlinelibrary.wiley.com/doi/10.1002/cam4.1515 https://onlinelibrary.wiley.com/doi/10.1002/cam4.1515

BROWN L M , COOKE D T , JETT J R , et al . Extent of resection and lymph node assessment for clinical stage T 1a N 0 M 0 typical carcinoid tumors [J ] . Ann Thorac Surg , 2018 , 105 ( 1 ): 207 - 213 . DOI: 10.1016/j.athoracsur.2017.07.049 http://doi.org/10.1016/j.athoracsur.2017.07.049 https://linkinghub.elsevier.com/retrieve/pii/S0003497517311001 https://linkinghub.elsevier.com/retrieve/pii/S0003497517311001

KNEUERTZ P J , KAMEL M K , STILES B M , et al . Incidence and prognostic significance of carcinoid lymph node metastases [J ] . Ann Thorac Surg , 2018 , 106 ( 4 ): 981 - 988 . DOI: 10.1016/j.athoracsur.2018.05.044 http://doi.org/10.1016/j.athoracsur.2018.05.044 https://linkinghub.elsevier.com/retrieve/pii/S0003497518308439 https://linkinghub.elsevier.com/retrieve/pii/S0003497518308439

DE LAAT J M , PIETERMAN C R , et al .VAN DEN BROEK M F, Natural course and survival of neuroendocrine tumors of thymus and lung in MEN1 patients [J ] . J Clin Endocrinol Metab , 2014 , 99 ( 9 ): 3325 - 3333 . DOI: 10.1210/jc.2014-1560 http://doi.org/10.1210/jc.2014-1560 https://academic.oup.com/jcem/article/99/9/3325/2538484 https://academic.oup.com/jcem/article/99/9/3325/2538484

YE L , WANG W , OSPINA N S , et al . Clinical features and prognosis of thymic neuroendocrine tumours associated with multiple endocrine neoplasia type 1: a single-centre study, systematic review and meta-analysis [J ] . Clinical endocrinology , 2017 , 87 ( 6 ): 706 - 16 . DOI: 10.1111/cen.13480 http://doi.org/10.1111/cen.13480 https://onlinelibrary.wiley.com/doi/10.1111/cen.13480 https://onlinelibrary.wiley.com/doi/10.1111/cen.13480

FRILLING A , MODLIN I M , KIDD M , et al . Recommendations for management of patients with neuroendocrine liver metastases [J ] . Lancet Oncol , 2014 , 15 ( 1 ): e8-e21 .

PARTELLI S , BARTSCH D K , CAPDEVILA J , et al . ENETS consensus guidelines for the standards of care in neuroendocrine tumours: surgery for small intestinal and pancreatic neuroendocrine tumours [J ] . Neuroendocrinology , 2017 , 105 ( 3 ): 255 - 265 . DOI: 10.1159/000464292 http://doi.org/10.1159/000464292 https://www.karger.com/Article/FullText/464292 https://www.karger.com/Article/FullText/464292

LEWIS A , RAOOF M , ITUARTE P H G , et al . Resection of the primary gastrointestinal neuroendocrine tumor improves survival with or without liver treatment [J ] . Ann Surg , 2019 , 270 ( 6 ): 1131 - 1137 . DOI: 10.1097/SLA.0000000000002809 http://doi.org/10.1097/SLA.0000000000002809 https://journals.lww.com/10.1097/SLA.0000000000002809 https://journals.lww.com/10.1097/SLA.0000000000002809

PARTELLI S , INAMA M , RINKE A , et al . Long-term outcomes of surgical management of pancreatic neuroendocrine tumors with synchronous liver metastases [J ] . Neuroendocrinology , 2015 , 102 ( 1/2 ): 68 - 76 . DOI: 10.1159/000431379 http://doi.org/10.1159/000431379 https://www.karger.com/Article/FullText/431379 https://www.karger.com/Article/FullText/431379

BERTANI E , FAZIO N , RADICE D , et al . Resection of the primary tumor followed by peptide receptor radionuclide therapy as upfront strategy for the treatment of G1-G2 pancreatic neuroendocrine tumors with unresectable liver metastases [J ] . Ann Surg Oncol , 2016 , 23 ( Suppl 5 ): 981 - 989 . DOI: 10.1245/s10434-016-5550-3 http://doi.org/10.1245/s10434-016-5550-3 http://link.springer.com/10.1245/s10434-016-5550-3 http://link.springer.com/10.1245/s10434-016-5550-3

KEUTGEN X M , NILUBOL N , GLANVILLE J , et al . Resection of primary tumor site is associated with prolonged survival in metastatic nonfunctioning pancreatic neuroendocrine tumors [J ] . Surgery , 2016 , 159 ( 1 ): 311 - 318 . DOI: 10.1016/j.surg.2015.05.042 http://doi.org/10.1016/j.surg.2015.05.042 https://linkinghub.elsevier.com/retrieve/pii/S0039606015007023 https://linkinghub.elsevier.com/retrieve/pii/S0039606015007023

CHEN L H , CHEN J . Perspective of neo-adjuvant/conversion and adjuvant therapy for pancreatic neuroendocrine tumors [J ] . J Pancreatol , 2019 , 2 ( 3 ): 91 - 99 . DOI: 10.1097/JP9.0000000000000023 http://doi.org/10.1097/JP9.0000000000000023 https://journals.lww.com/02070903-201909000-00006 https://journals.lww.com/02070903-201909000-00006

VEZZOSI D , BENNET A , ROCHAIX P , et al . Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies [J ] . Eur J Endocrinol , 2005 , 152 ( 5 ): 757 - 767 . DOI: 10.1530/eje.1.01901 http://doi.org/10.1530/eje.1.01901 https://eje.bioscientifica.com/view/journals/eje/152/5/1520757.xml https://eje.bioscientifica.com/view/journals/eje/152/5/1520757.xml

WOLTERING E A , WRIGHT A E , STEVENS M A , et al . Development of effective prophylaxis against intraoperative carcinoid crisis [J ] . J Clin Anesth , 2016 , 32 : 189 - 193 . DOI: 10.1016/j.jclinane.2016.03.008 http://doi.org/10.1016/j.jclinane.2016.03.008 https://linkinghub.elsevier.com/retrieve/pii/S0952818016300150 https://linkinghub.elsevier.com/retrieve/pii/S0952818016300150

BAUDIN E , CAPLIN M , GARCIA-CARBONERO R , et al . Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J ] . Ann Oncol , 2021 , 32 ( 4 ): 439 - 451 . DOI: 10.1016/j.annonc.2021.01.003 http://doi.org/10.1016/j.annonc.2021.01.003 https://linkinghub.elsevier.com/retrieve/pii/S0923753421000119 https://linkinghub.elsevier.com/retrieve/pii/S0923753421000119

WOLIN E M , BENSON III A B . Systemic treatment options for carcinoid syndrome: a systematic review [J ] . Oncology , 2019 , 96 ( 6 ): 273 - 289 . DOI: 10.1159/000499049 http://doi.org/10.1159/000499049 https://www.karger.com/Article/FullText/499049 https://www.karger.com/Article/FullText/499049

BRODER M S , BEENHOUWER D , STROSBERG J R , et al . Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature review [J ] . World J Gastroenterol , 2015 , 21 ( 6 ): 1945 - 1955 . DOI: 10.3748/wjg.v21.i6.1945 http://doi.org/10.3748/wjg.v21.i6.1945 http://www.wjgnet.com/1007-9327/full/v21/i6/1945.htm http://www.wjgnet.com/1007-9327/full/v21/i6/1945.htm

PAVEL M , VALLE J W , ERIKSSON B , et al . ENETS consensus guidelines for the standards of care in neuroendocrine neoplasms: systemic therapy-biotherapy and novel targeted agents [J ] . Neuroendocrinology , 2017 , 105 ( 3 ): 266 - 280 . DOI: 10.1159/000471880 http://doi.org/10.1159/000471880 https://www.karger.com/Article/FullText/471880 https://www.karger.com/Article/FullText/471880

WOLIN E M , JARZAB B , ERIKSSON B , et al . Phase Ⅲ study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues [J ] . Drug Des Devel Ther , 2015 , 9 : 5075 - 5086 .

OBERG K . Interferon in the management of neuroendocrine GEP-tumors: a review [J ] . Digestion , 2000 , 62 ( Suppl 1 ): 92 - 97 . DOI: 10.1159/000051862 http://doi.org/10.1159/000051862 https://www.karger.com/Article/FullText/51862 https://www.karger.com/Article/FullText/51862

PAVEL M , GROSS D J , BENAVENT M , et al . Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial [J ] . Endocr Relat Cancer , 2018 , 25 ( 3 ): 309 - 322 . DOI: 10.1530/ERC-17-0455 http://doi.org/10.1530/ERC-17-0455 https://erc.bioscientifica.com/view/journals/erc/25/3/ERC-17-0455.xml https://erc.bioscientifica.com/view/journals/erc/25/3/ERC-17-0455.xml

ITO T , LEE L , JENSEN R T . Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies [J ] . Expert Opin Pharmacother , 2016 , 17 ( 16 ): 2191 - 2205 . DOI: 10.1080/14656566.2016.1236916 http://doi.org/10.1080/14656566.2016.1236916 https://www.tandfonline.com/doi/full/10.1080/14656566.2016.1236916 https://www.tandfonline.com/doi/full/10.1080/14656566.2016.1236916

DANIEL E , AYLWIN S , MUSTAFA O , et al . Effectiveness of metyrapone in treating Cushing’s syndrome: a retrospective multicenter study in 195 patients [J ] . J Clin Endocrinol Metab , 2015 , 100 ( 11 ): 4146 - 4154 . DOI: 10.1210/jc.2015-2616 http://doi.org/10.1210/jc.2015-2616 https://academic.oup.com/jcem/article-lookup/doi/10.1210/jc.2015-2616 https://academic.oup.com/jcem/article-lookup/doi/10.1210/jc.2015-2616

YUEN K C J , WILLIAMS G , KUSHNER H , et al . Association between mifepristone dose, efficacy, and tolerability in patients with cushing syndrome [J ] . Endocr Pract , 2015 , 21 ( 10 ): 1087 - 1093 . DOI: 10.4158/EP15760.OR http://doi.org/10.4158/EP15760.OR https://linkinghub.elsevier.com/retrieve/pii/S1530891X20355336 https://linkinghub.elsevier.com/retrieve/pii/S1530891X20355336

RINKE A , MÜLLER H H , SCHADE-BRITTINGER C , et al . Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group [J ] . J Clin Oncol , 2009 , 27 ( 28 ): 4656 - 4663 . DOI: 10.1200/JCO.2009.22.8510 http://doi.org/10.1200/JCO.2009.22.8510 https://ascopubs.org/doi/10.1200/JCO.2009.22.8510 https://ascopubs.org/doi/10.1200/JCO.2009.22.8510

YAO J C , PAVEL M , LOMBARD-BOHAS C , et al . Everolimus for the treatment of advanced pancreatic neuroendocrine tumors: Overall survival and circulating biomarkers from the randomized, phase Ⅲ RADIANT-3 study [J ] . J Clin Oncol , 2016 , 34 ( 32 ): 3906 - 3913 . DOI: 10.1200/JCO.2016.68.0702 http://doi.org/10.1200/JCO.2016.68.0702 https://ascopubs.org/doi/10.1200/JCO.2016.68.0702 https://ascopubs.org/doi/10.1200/JCO.2016.68.0702

YAO J C , FAZIO N , SINGH S , et al . Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study [J ] . Lancet , 2016 , 387 ( 10022 ): 968 - 977 . DOI: 10.1016/S0140-6736(15)00817-X http://doi.org/10.1016/S0140-6736(15)00817-X https://linkinghub.elsevier.com/retrieve/pii/S014067361500817X https://linkinghub.elsevier.com/retrieve/pii/S014067361500817X

KULKE M H , RUSZNIEWSKI P , VAN CUTSEM E , et al . A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial [J ] . Ann Oncol , 2019 , 30 ( 11 ): 1846 . DOI: 10.1093/annonc/mdz219 http://doi.org/10.1093/annonc/mdz219 https://linkinghub.elsevier.com/retrieve/pii/S0923753420325825 https://linkinghub.elsevier.com/retrieve/pii/S0923753420325825

PAVEL M E , HAINSWORTH J D , BAUDIN E , et al . Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study [J ] . Lancet , 2011 , 378 ( 9808 ): 2005 - 2012 . DOI: 10.1016/S0140-6736(11)61742-X http://doi.org/10.1016/S0140-6736(11)61742-X https://linkinghub.elsevier.com/retrieve/pii/S014067361161742X https://linkinghub.elsevier.com/retrieve/pii/S014067361161742X

PANZUTO F , RINZIVILLO M , SPADA F , et al . Everolimus in pancreatic neuroendocrine carcinomas G3 [J ] . Pancreas , 2017 , 46 ( 3 ): 302 - 305 . DOI: 10.1097/MPA.0000000000000762 http://doi.org/10.1097/MPA.0000000000000762 https://journals.lww.com/00006676-201703000-00004 https://journals.lww.com/00006676-201703000-00004

FAIVRE S , NICCOLI P , CASTELLANO D , et al . Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase Ⅲ randomized study [J ] . Ann Oncol , 2017 , 28 ( 2 ): 339 - 343 . DOI: 10.1093/annonc/mdw561 http://doi.org/10.1093/annonc/mdw561 https://linkinghub.elsevier.com/retrieve/pii/S0923753419322082 https://linkinghub.elsevier.com/retrieve/pii/S0923753419322082

CAPDEVILA J , FAZIO N , LÓPEZ C , et al . Lenvatinib in patients with advanced grade 1/2 pancreatic and gastrointestinal neuroendocrine tumors: results of the phase Ⅱ TALENT trial (GETNE1509) [J ] . J Clin Oncol , 2021 , 39 ( 20 ): JCO2003368.

PAVEL M , O'TOOLE D , COSTA F , et al . ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site [J ] . Neuroendocrinology , 2016 , 103 ( 2 ): 172 - 185 . DOI: 10.1159/000443167 http://doi.org/10.1159/000443167 https://www.karger.com/Article/FullText/443167 https://www.karger.com/Article/FullText/443167

CLEWEMAR ANTONODIMITRAKIS P , SUNDIN A , WASSBERG C , et al . Streptozocin and 5-fluorouracil for the treatment of pancreatic neuroendocrine tumors: efficacy, prognostic factors and toxicity [J ] . Neuroendocrinology , 2016 , 103 ( 3/4 ): 345 - 353 . DOI: 10.1159/000439086 http://doi.org/10.1159/000439086 https://www.karger.com/Article/FullText/439086 https://www.karger.com/Article/FullText/439086

CHATZELLIS E , ANGELOUSI A , DASKALAKIS K , et al . activity and safety of standard and prolonged capecitabine/temozolomide administration in patients with advanced neuroendocrine neoplasms [J ] . Neuroendocrinology , 2019 , 109 ( 4 ): 333 - 45 . DOI: 10.1159/000500135 http://doi.org/10.1159/000500135 https://www.karger.com/Article/FullText/500135 https://www.karger.com/Article/FullText/500135

LAMARCA A , ELLIOTT E , BARRIUSO J , et al . Chemotherapy for advanced non-pancreatic well-differentiated neuroendocrine tumours of the gastrointestinal tract, a systematic review and meta-analysis: a lost cause? [J ] . Cancer Treat Rev , 2016 , 44 : 26 - 41 . DOI: 10.1016/j.ctrv.2016.01.005 http://doi.org/10.1016/j.ctrv.2016.01.005 https://linkinghub.elsevier.com/retrieve/pii/S030573721600013X https://linkinghub.elsevier.com/retrieve/pii/S030573721600013X

GARCIA-CARBONERO R , SORBYE H , BAUDIN E , et al . ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas [J ] . Neuroendocrinology , 2016 , 103 ( 2 ): 186 - 194 . DOI: 10.1159/000443172 http://doi.org/10.1159/000443172 https://www.karger.com/Article/FullText/443172 https://www.karger.com/Article/FullText/443172

SORBYE H , WELIN S , LANGER S W , et al . Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study [J ] . Ann Oncol , 2013 , 24 ( 1 ): 152 - 160 . DOI: 10.1093/annonc/mds276 http://doi.org/10.1093/annonc/mds276 https://linkinghub.elsevier.com/retrieve/pii/S0923753419370486 https://linkinghub.elsevier.com/retrieve/pii/S0923753419370486

SORBYE H , BAUDIN E , PERREN A . The problem of high-grade gastroenteropancreatic neuroendocrine neoplasms: well-differentiated neuroendocrine tumors, neuroendocrine carcinomas, and beyond [J ] . Endocrinol Metab Clin North Am , 2018 , 47 ( 3 ): 683 - 698 . DOI: 10.1016/j.ecl.2018.05.001 http://doi.org/10.1016/j.ecl.2018.05.001 https://linkinghub.elsevier.com/retrieve/pii/S0889852918305279 https://linkinghub.elsevier.com/retrieve/pii/S0889852918305279

WELIN S , SORBYE H , SEBJORNSEN S , et al . Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy [J ] . Cancer , 2011 , 117 ( 20 ): 4617 - 4622 . DOI: 10.1002/cncr.26124 http://doi.org/10.1002/cncr.26124 https://onlinelibrary.wiley.com/doi/10.1002/cncr.26124 https://onlinelibrary.wiley.com/doi/10.1002/cncr.26124

STROSBERG J , MIZUNO N , DOI T , et al . Efficacy and safety of pembrolizumab in previously treated advanced neuroendocrine tumors: results from the phase Ⅱ KEYNOTE-158 study [J ] . Clin Cancer Res , 2020 , 26 ( 9 ): 2124 - 2130 . DOI: 10.1158/1078-0432.CCR-19-3014 http://doi.org/10.1158/1078-0432.CCR-19-3014 https://aacrjournals.org/clincancerres/article/26/9/2124/83112/Efficacy-and-Safety-of-Pembrolizumab-in-Previously https://aacrjournals.org/clincancerres/article/26/9/2124/83112/Efficacy-and-Safety-of-Pembrolizumab-in-Previously

FAIVRE-FINN C , SNEE M , ASHCROFT L , et al . Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial [J ] . Lancet Oncol , 2017 , 18 ( 8 ): 1116 - 1125 . DOI: 10.1016/S1470-2045(17)30318-2 http://doi.org/10.1016/S1470-2045(17)30318-2 https://linkinghub.elsevier.com/retrieve/pii/S1470204517303182 https://linkinghub.elsevier.com/retrieve/pii/S1470204517303182

SKARLOS D V , SAMANTAS E , BRIASSOULIS E , et al . Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: a randomized phase Ⅱ study of the Hellenic Cooperative Oncology Group (HeCOG) [J ] . Ann Oncol , 2001 , 12 ( 9 ): 1231 - 1238 . DOI: 10.1023/A:1012295131640 http://doi.org/10.1023/A:1012295131640 https://linkinghub.elsevier.com/retrieve/pii/S0923753419542909 https://linkinghub.elsevier.com/retrieve/pii/S0923753419542909

HORN L , MANSFIELD A S , SZCZĘSNA A , et al . First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer [J ] . N Engl J Med , 2018 , 379 ( 23 ): 2220 - 2229 . DOI: 10.1056/NEJMoa1809064 http://doi.org/10.1056/NEJMoa1809064 http://www.nejm.org/doi/10.1056/NEJMoa1809064 http://www.nejm.org/doi/10.1056/NEJMoa1809064

PAZ-ARES L , DVORKIN M , CHEN Y , et al . Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial [J ] . Lancet , 2019 , 394 ( 10212 ): 1929 - 1939 . DOI: 10.1016/S0140-6736(19)32222-6 http://doi.org/10.1016/S0140-6736(19)32222-6 https://linkinghub.elsevier.com/retrieve/pii/S0140673619322226 https://linkinghub.elsevier.com/retrieve/pii/S0140673619322226

EVANS W K , SHEPHERD F A , FELD R , et al . VP-16 and cisplatin as first-line therapy for small cell lung cancer [J ] . J Clin Oncol , 1985 , 3 ( 11 ): 1471 - 1477 . DOI: 10.1200/JCO.1985.3.11.1471 http://doi.org/10.1200/JCO.1985.3.11.1471 https://ascopubs.org/doi/10.1200/JCO.1985.3.11.1471 https://ascopubs.org/doi/10.1200/JCO.1985.3.11.1471

OKAMOTO H , WATANABE K , NISHIWAKI Y , et al . Phase Ⅱ study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small-cell lung cancer [J ] . J Clin Oncol , 1999 , 17 ( 11 ): 3540 - 3545 . DOI: 10.1200/JCO.1999.17.11.3540 http://doi.org/10.1200/JCO.1999.17.11.3540 https://ascopubs.org/doi/10.1200/JCO.1999.17.11.3540 https://ascopubs.org/doi/10.1200/JCO.1999.17.11.3540

NODA K , NISHIWAKI Y , KAWAHARA M , et al . Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer [J ] . N Engl J Med , 2002 , 346 ( 2 ): 85 - 91 . DOI: 10.1056/NEJMoa003034 http://doi.org/10.1056/NEJMoa003034 http://www.nejm.org/doi/abs/10.1056/NEJMoa003034 http://www.nejm.org/doi/abs/10.1056/NEJMoa003034

SCHMITTEL A , VON WEIKERSTHAL L F , SEBASTIAN M , et al . A randomized phase Ⅱ trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer [J ] . Ann Oncol , 2006 , 17 ( 4 ): 663 - 667 . DOI: 10.1093/annonc/mdj137 http://doi.org/10.1093/annonc/mdj137 https://linkinghub.elsevier.com/retrieve/pii/S0923753419575640 https://linkinghub.elsevier.com/retrieve/pii/S0923753419575640

MOERTEL C G , KVOLS L K , O’CONNELL M J , et al . Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms [J ] . Cancer , 1991 , 68 ( 2 ): 227 - 232 . DOI: 10.1002/1097-0142(19910715)68:2&lt;227::AID-CNCR2820680202&gt;3.0.CO;2-I http://doi.org/10.1002/1097-0142(19910715)68:2&lt;227::AID-CNCR2820680202&gt;3.0.CO;2-I https://onlinelibrary.wiley.com/doi/10.1002/1097-0142(19910715)68:2&lt;227::AID-CNCR2820680202&gt;3.0.CO;2-I https://onlinelibrary.wiley.com/doi/10.1002/1097-0142(19910715)68:2&lt;227::AID-CNCR2820680202&gt;3.0.CO;2-I

ZHANG P P , LI J , LI J , et al . Etoposide and cisplatin versus irinotecan and cisplatin as the first-line therapy for patients with advanced, poorly differentiated gastroenteropancreatic neuroendocrine carcinoma: a randomized phase 2 study [J ] . Cancer , 2020 , 126 ( Suppl 9 ): 2086 - 2092 . DOI: 10.1002/cncr.32750 http://doi.org/10.1002/cncr.32750 https://onlinelibrary.wiley.com/doi/10.1002/cncr.32750 https://onlinelibrary.wiley.com/doi/10.1002/cncr.32750

FINE R L , GULATI A P , KRANTZ B A , et al . Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: the Pancreas Center at Columbia University experience [J ] . Cancer Chemother Pharmacol , 2013 , 71 ( 3 ): 663 - 670 . DOI: 10.1007/s00280-012-2055-z http://doi.org/10.1007/s00280-012-2055-z http://link.springer.com/10.1007/s00280-012-2055-z http://link.springer.com/10.1007/s00280-012-2055-z

OKITA N T , KATO K , TAKAHARI D , et al . Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma [J ] . Gastric Cancer , 2011 , 14 ( 2 ): 161 - 165 . DOI: 10.1007/s10120-011-0025-5 http://doi.org/10.1007/s10120-011-0025-5 http://link.springer.com/10.1007/s10120-011-0025-5 http://link.springer.com/10.1007/s10120-011-0025-5

BAJETTA E , CATENA L , PROCOPIO G , et al . Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? [J ] . Cancer Chemother Pharmacol , 2007 , 59 ( 5 ): 637 - 642 . DOI: 10.1007/s00280-006-0306-6 http://doi.org/10.1007/s00280-006-0306-6 http://link.springer.com/10.1007/s00280-006-0306-6 http://link.springer.com/10.1007/s00280-006-0306-6

LE D T , DURHAM J N , SMITH K N , et al . Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade [J ] . Science , 2017 , 357 ( 6349 ): 409 - 413 . DOI: 10.1126/science.aan6733 http://doi.org/10.1126/science.aan6733 https://www.science.org/doi/10.1126/science.aan6733 https://www.science.org/doi/10.1126/science.aan6733

HICKS R J , KWEKKEBOOM D J , KRENNING E , et al . ENETS consensus guidelines for the standards of care in neuroendocrine neoplasia: peptide receptor radionuclide therapy with radiolabeled somatostatin analogues [J ] . Neuroendocrinology , 2017 , 105 ( 3 ): 295 - 309 . DOI: 10.1159/000475526 http://doi.org/10.1159/000475526 https://www.karger.com/Article/FullText/475526 https://www.karger.com/Article/FullText/475526

CARLSEN E A , FAZIO N , GRANBERG D , et al . Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study [J ] . Endocr Relat Cancer , 2019 , 26 ( 2 ): 227 - 239 .

CARMONA-BAYONAS A , JIMÉNEZ-FONSECA P , LAMARCA Á , et al . Prediction of progression-free survival in patients with advanced, well-differentiated, neuroendocrine tumors being treated with a somatostatin analog: the GETNE-TRASGU study [J ] . J Clin Oncol , 2019 , 37 ( 28 ): 2571 - 2580 . DOI: 10.1200/JCO.19.00980 http://doi.org/10.1200/JCO.19.00980 https://ascopubs.org/doi/10.1200/JCO.19.00980 https://ascopubs.org/doi/10.1200/JCO.19.00980

WANG Y H , LIN Y , XUE L , et al . Relationship between clinical characteristics and survival of gastroenteropancreatic neuroendocrine neoplasms: a single-institution analysis (1995-2012) in South China [J ] . BMC Endocr Disord , 2012 , 12 : 30 . DOI: 10.1186/1472-6823-12-30 http://doi.org/10.1186/1472-6823-12-30 https://bmcendocrdisord.biomedcentral.com/articles/10.1186/1472-6823-12-30 https://bmcendocrdisord.biomedcentral.com/articles/10.1186/1472-6823-12-30

FRILLING A , LI J , MALAMUTMANN E , et al . Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease [J ] . Br J Surg , 2009 , 96 ( 2 ): 175 - 184 . DOI: 10.1002/bjs.6468 http://doi.org/10.1002/bjs.6468 https://academic.oup.com/bjs/article/96/2/175/6150209 https://academic.oup.com/bjs/article/96/2/175/6150209

MOHAN H , NICHOLSON P , WINTER D C , et al . Radiofrequency ablation for neuroendocrine liver metastases: a systematic review [J ] . J Vasc Interv Radiol , 2015 , 26 ( 7 ): 935-942.e1.

FAIRWEATHER M , SWANSON R , WANG J P , et al . Management of neuroendocrine tumor liver metastases: long-term outcomes and prognostic factors from a large prospective database [J ] . Ann Surg Oncol , 2017 , 24 ( 8 ): 2319 - 2325 . DOI: 10.1245/s10434-017-5839-x http://doi.org/10.1245/s10434-017-5839-x http://link.springer.com/10.1245/s10434-017-5839-x http://link.springer.com/10.1245/s10434-017-5839-x

NORLÉN O , STÅLBERG P , ZEDENIUS J , et al . Outcome after resection and radiofrequency ablation of liver metastases from small intestinal neuroendocrine tumours [J ] . Br J Surg , 2013 , 100 ( 11 ): 1505 - 1514 . DOI: 10.1002/bjs.9262 http://doi.org/10.1002/bjs.9262 https://academic.oup.com/bjs/article/100/11/1505-1514/6138556 https://academic.oup.com/bjs/article/100/11/1505-1514/6138556

AKYILDIZ H Y , MITCHELL J , MILAS M , et al . Laparoscopic radiofrequency thermal ablation of neuroendocrine hepatic metastases: long-term follow-up [J ] . Surgery , 2010 , 148 ( 6 ): 1288 - 1293 . DOI: 10.1016/j.surg.2010.09.014 http://doi.org/10.1016/j.surg.2010.09.014 https://linkinghub.elsevier.com/retrieve/pii/S0039606010005064 https://linkinghub.elsevier.com/retrieve/pii/S0039606010005064

STROSBERG J R , CHEEMA A , KVOLS L K . A review of systemic and liver-directed therapies for metastatic neuroendocrine tumors of the gastroenteropancreatic tract [J ] . Cancer Control , 2011 , 18 ( 2 ): 127 - 137 . DOI: 10.1177/107327481101800207 http://doi.org/10.1177/107327481101800207 http://journals.sagepub.com/doi/10.1177/107327481101800207 http://journals.sagepub.com/doi/10.1177/107327481101800207

PERICLEOUS M , CAPLIN M E , TSOCHATZIS E , et al . Hepatic artery embolization in advanced neuroendocrine tumors: efficacy and long-term outcomes [J ] . Asia Pac J Clin Oncol , 2016 , 12 ( 1 ): 61 - 69 . DOI: 10.1111/ajco.12438 http://doi.org/10.1111/ajco.12438 https://onlinelibrary.wiley.com/doi/10.1111/ajco.12438 https://onlinelibrary.wiley.com/doi/10.1111/ajco.12438

刘一铭 , 连帆 , 周翔飞 , 等 . 肝动脉栓塞术联合长效奥曲肽降低中低级别神经内分泌瘤肝转移负荷的疗效及安全性分析 [J ] . 中华医学杂志 , 2019 , 99 ( 15 ): 1142 - 1146 .

LIU Y M , LIAN F , ZHOU X F , et al . Safety and efficacy of transarterial embolization combined with octreotide LAR on reducing tumor burden for neuroendocrine tumor liver metastasis [J ] . Natl Med J China , 2019 , 99 ( 15 ): 1142 - 1146 .

刘海宽 , 陈文川 , 刘一铭 , 等 . 肝动脉栓塞术治疗42例低-中级别乏血供型神经内分泌肿瘤肝转移的近期疗效及安全性分析 [J ] . 中华介入放射学电子杂志 , 2020 , 8 ( 2 ): 130 - 134 .

LIU H K , CHEN W C , LIU Y M , et al . Transarterial embolization in the treatment of 42 patients with low-to-intermediate grade neuroendocrine neoplasm liver metastasis with hypovascular pattern: an analysis of the short-term efficacy and safety [J ] . Chin J Interv Radiol Electron Ed , 2020 , 8 ( 2 ): 130 - 134 .

王于 , 陈洁 . 胰腺神经内分泌肿瘤复杂肝转移的介入及药物治疗策略 [J ] . 协和医学杂志 , 2020 , 11 ( 4 ): 389 - 394 .

WANG Y , CHEN J . The management strategies of interventional therapy and drug therapy of complicated pancreatic neuroendocrine neoplasms with liver metastases [J ] . Med J Peking Union Med Coll Hosp , 2020 , 11 ( 4 ): 389 - 394 .

FRILLING A , CLIFT A K . Therapeutic strategies for neuroendocrine liver metastases [J ] . Cancer , 2015 , 121 ( 8 ): 1172 - 1186 . DOI: 10.1002/cncr.28760 http://doi.org/10.1002/cncr.28760 https://onlinelibrary.wiley.com/doi/10.1002/cncr.28760 https://onlinelibrary.wiley.com/doi/10.1002/cncr.28760

DEL PRETE M , FIORE F , MODICA R , et al . Hepatic arterial embolization in patients with neuroendocrine tumors [J ] . J Exp Clin Cancer Res , 2014 , 33 ( 1 ): 43 . DOI: 10.1186/1756-9966-33-43 http://doi.org/10.1186/1756-9966-33-43 https://doi.org/10.1186/1756-9966-33-43 https://doi.org/10.1186/1756-9966-33-43

ZENER R , YOON H , ZIV E , et al . Outcomes after transarterial embolization of neuroendocrine tumor liver metastases using spherical particles of different sizes [J ] . Cardiovasc Intervent Radiol , 2019 , 42 ( 4 ): 569 - 576 . DOI: 10.1007/s00270-018-02160-y http://doi.org/10.1007/s00270-018-02160-y https://doi.org/10.1007/s00270-018-02160-y https://doi.org/10.1007/s00270-018-02160-y

ENGELMAN E S , LEON-FERRE R , NARAEV B G , et al . Comparison of transarterial liver-directed therapies for low-grade metastatic neuroendocrine tumors in a single institution [J ] . Pancreas , 2014 , 43 ( 2 ): 219 - 225 . DOI: 10.1097/MPA.0000000000000030 http://doi.org/10.1097/MPA.0000000000000030 https://journals.lww.com/00006676-201403000-00007 https://journals.lww.com/00006676-201403000-00007

SAXENA A , CHUA T C , BESTER L , et al . Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumor liver metastases: a critical appraisal of 48 cases [J ] . Ann Surg , 2010 , 251 ( 5 ): 910 - 916 . DOI: 10.1097/SLA.0b013e3181d3d24a http://doi.org/10.1097/SLA.0b013e3181d3d24a https://journals.lww.com/00000658-201005000-00019 https://journals.lww.com/00000658-201005000-00019

BHAGAT N , REYES D K , LIN M D , et al . Phase Ⅱ study of chemoembolization with drug-eluting beads in patients with hepatic neuroendocrine metastases: high incidence of biliary injury [J ] . Cardiovasc Intervent Radiol , 2013 , 36 ( 2 ): 449 - 459 . DOI: 10.1007/s00270-012-0424-y http://doi.org/10.1007/s00270-012-0424-y http://link.springer.com/10.1007/s00270-012-0424-y http://link.springer.com/10.1007/s00270-012-0424-y

BEAN M B , LIU Y , JIANG R , et al . Small cell and squamous cell carcinomas of the head and neck: comparing incidence and survival trends based on surveillance, epidemiology, and end results (SEER) data [J ] . Oncologist , 2019 , 24 ( 12 ): 1562 - 1569 . DOI: 10.1634/theoncologist.2018-0054 http://doi.org/10.1634/theoncologist.2018-0054 https://academic.oup.com/oncolo/article/24/12/1562/6439525 https://academic.oup.com/oncolo/article/24/12/1562/6439525

VAN DER LAAN T P , IEPSMA R , WITJES M J , et al . Meta-analysis of 701 published cases of sinonasal neuroendocrine carcinoma: the importance of differentiation grade in determining treatment strategy [J ] . Oral Oncol , 2016 , 63 : 1 - 9 . DOI: 10.1016/j.oraloncology.2016.10.002 http://doi.org/10.1016/j.oraloncology.2016.10.002 https://linkinghub.elsevier.com/retrieve/pii/S1368837516301786 https://linkinghub.elsevier.com/retrieve/pii/S1368837516301786

POINTER K B , KO H C , BROWER J V , et al . Small cell carcinoma of the head and neck: an analysis of the National Cancer Database [J ] . Oral Oncol , 2017 , 69 : 92 - 98 . DOI: 10.1016/j.oraloncology.2017.04.009 http://doi.org/10.1016/j.oraloncology.2017.04.009 https://linkinghub.elsevier.com/retrieve/pii/S1368837517301008 https://linkinghub.elsevier.com/retrieve/pii/S1368837517301008

CHUN S G , SIMONE C B, 2ND , AMINI A , et al . American Radium Society appropriate use criteria: radiation therapy for limited-stage SCLC 2020 [J ] . J Thorac Oncol , 2021 , 16 ( 1 ): 66 - 75 . DOI: 10.1016/j.jtho.2020.10.020 http://doi.org/10.1016/j.jtho.2020.10.020 https://linkinghub.elsevier.com/retrieve/pii/S1556086420308467 https://linkinghub.elsevier.com/retrieve/pii/S1556086420308467

GRØNBERG B H , KILLINGBERG K T , FLØTTEN Ø , et al . High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial [J ] . Lancet Oncol , 2021 , 22 ( 3 ): 321 - 331 . DOI: 10.1016/S1470-2045(20)30742-7 http://doi.org/10.1016/S1470-2045(20)30742-7 https://linkinghub.elsevier.com/retrieve/pii/S1470204520307427 https://linkinghub.elsevier.com/retrieve/pii/S1470204520307427

EXPERT PANEL THORACIC MALIGNANCIES: , HIGGINS K A , SIMONE C B 2nd , et al . American Radium Society appropriate use criteria on radiation therapy for extensive-stage SCLC [J ] . J Thorac Oncol , 2021 , 16 ( 1 ): 54 - 65 . DOI: 10.1016/j.jtho.2020.09.013 http://doi.org/10.1016/j.jtho.2020.09.013 https://linkinghub.elsevier.com/retrieve/pii/S1556086420307590 https://linkinghub.elsevier.com/retrieve/pii/S1556086420307590

MAY M S , KINSLOW C J , ADAMS C , et al . Outcomes for localized treatment of large cell neuroendocrine carcinoma of the lung in the United States [J ] . Transl Lung Cancer Res , 2021 , 10 ( 1 ): 71 - 79 . DOI: 10.21037/tlcr-20-374 http://doi.org/10.21037/tlcr-20-374 https://tlcr.amegroups.com/article/view/48348/html https://tlcr.amegroups.com/article/view/48348/html

WEGNER R E , ABEL S , HASAN S , et al . The role of adjuvant therapy for atypical bronchopulmonary carcinoids [J ] . Lung Cancer , 2019 , 131 : 90 - 94 . DOI: 10.1016/j.lungcan.2019.03.022 http://doi.org/10.1016/j.lungcan.2019.03.022 https://linkinghub.elsevier.com/retrieve/pii/S0169500219303782 https://linkinghub.elsevier.com/retrieve/pii/S0169500219303782

UPRETY D , HALFDANARSON T R , MOLINA J R , et al . Pulmonary neuroendocrine tumors: adjuvant and systemic treatments [J ] . Curr Treat Options Oncol , 2020 , 21 ( 11 ): 86 . DOI: 10.1007/s11864-020-00786-0 http://doi.org/10.1007/s11864-020-00786-0 https://doi.org/10.1007/s11864-020-00786-0 https://doi.org/10.1007/s11864-020-00786-0

ZHAO Y , GU H Y , FAN L M , et al . Comparison of clinical features and survival between thymic carcinoma and thymic carcinoid patients [J ] . Eur J Cardiothorac Surg , 2017 , 52 ( 1 ): 33 - 38 . DOI: 10.1093/ejcts/ezx037 http://doi.org/10.1093/ejcts/ezx037 https://academic.oup.com/ejcts/article-lookup/doi/10.1093/ejcts/ezx037 https://academic.oup.com/ejcts/article-lookup/doi/10.1093/ejcts/ezx037

CATTRINI C , CERBONE L , RUBAGOTTI A , et al . Prognostic variables in patients with non-metastatic small-cell neuroendocrine carcinoma of the bladder: a population-based study [J ] . Clin Genitourin Cancer , 2019 , 17 ( 4 ): e724-e732.

LIM J H , SUNDAR S . Prognosis of early stage small cell bladder cancer is not always dismal [J ] . ESMO Open , 2019 , 4 ( 6 ): e000559.

NIU Q , LU Y Y , XU S G , et al . Clinicopathological characteristics and survival outcomes of bladder neuroendocrine carcinomas: a population-based study [J ] . Cancer Manag Res , 2018 , 10 : 4479 - 4489 . DOI: 10.2147/CMAR.S175286 http://doi.org/10.2147/CMAR.S175286 https://www.dovepress.com/clinicopathological-characteristics-and-survival-outcomes-of-bladder-n-peer-reviewed-article-CMAR https://www.dovepress.com/clinicopathological-characteristics-and-survival-outcomes-of-bladder-n-peer-reviewed-article-CMAR

TEMPFER C B , TISCHOFF I , DOGAN A , et al . Neuroendocrine carcinoma of the cervix: a systematic review of the literature [J ] . BMC Cancer , 2018 , 18 ( 1 ): 530 . DOI: 10.1186/s12885-018-4447-x http://doi.org/10.1186/s12885-018-4447-x https://doi.org/10.1186/s12885-018-4447-x https://doi.org/10.1186/s12885-018-4447-x

PANG L , YANG H , NING Y E , et al . Retrospective analysis of clinicopathological features and prognosis of gynecological small-cell carcinoma [J ] . Cancer Manag Res , 2021 , 13 : 4529 - 4540 . DOI: 10.2147/CMAR.S314686 http://doi.org/10.2147/CMAR.S314686 https://www.dovepress.com/retrospective-analysis-of-clinicopathological-features-and-prognosis-o-peer-reviewed-fulltext-article-CMAR https://www.dovepress.com/retrospective-analysis-of-clinicopathological-features-and-prognosis-o-peer-reviewed-fulltext-article-CMAR

DONG M L , GU X B , MA T R , et al . The role of radiotherapy in neuroendocrine cervical cancer: SEER-based study [J ] . Sci Prog , 2021 , 104 ( 2 ): 368504211009336 .

LIN L M , LIN Q , LIU J , et al . Prognostic factors and treatment comparison in small cell neuroendocrine carcinoma of the uterine cervix based on population analyses [J ] . Cancer Med , 2020 , 9 ( 18 ): 6524 - 6532 . DOI: 10.1002/cam4.3326 http://doi.org/10.1002/cam4.3326 https://onlinelibrary.wiley.com/doi/10.1002/cam4.3326 https://onlinelibrary.wiley.com/doi/10.1002/cam4.3326

BHATIA S , STORER B E , IYER J G , et al . Adjuvant radiation therapy and chemotherapy in merkel cell carcinoma: survival analyses of 6 908 cases from the national cancer data base [J ] . J Natl Cancer Inst , 2016 , 108 ( 9 ): djw042.

ANDRUSKA N , FISCHER-VALUCK B W , MAHAPATRA L , et al . Association between surgical margins larger than 1 cm and overall survival in patients with Merkel cell carcinoma [J ] . JAMA Dermatol , 2021 , 157 ( 5 ): 540 - 548 . DOI: 10.1001/jamadermatol.2021.0247 http://doi.org/10.1001/jamadermatol.2021.0247 https://jamanetwork.com/journals/jamadermatology/fullarticle/2777665 https://jamanetwork.com/journals/jamadermatology/fullarticle/2777665

ANDRUSKA N , MAHAPATRA L , BRENNEMAN R J , et al . Regional lymph node irradiation in locally advanced Merkel cell carcinoma reduces regional and distant relapse and improves disease-specific survival [J ] . Radiother Oncol , 2021 , 155 : 246 - 253 . DOI: 10.1016/j.radonc.2020.11.003 http://doi.org/10.1016/j.radonc.2020.11.003 https://linkinghub.elsevier.com/retrieve/pii/S0167814020311579 https://linkinghub.elsevier.com/retrieve/pii/S0167814020311579

CHEN Y Y , HAN D , ZHU J Q , et al . A prospective and retrospective clinical controlled observation of Chinese herbal decoction (SMLJ01) for type 1 gastric neuroendocrine tumors [J ] . Integr Cancer Ther , 2020 , 19 : 1534735420958488 .

LAMB B W , SEVDALIS N , VINCENT C , et al . Development and evaluation of a checklist to support decision making in cancer multidisciplinary team meetings: MDT-QuIC [J ] . Ann Surg Oncol , 2012 , 19 ( 6 ): 1759 - 1765 . DOI: 10.1245/s10434-011-2187-0 http://doi.org/10.1245/s10434-011-2187-0 http://link.springer.com/10.1245/s10434-011-2187-0 http://link.springer.com/10.1245/s10434-011-2187-0

TAMAGNO G , SHEAHAN K , SKEHAN S J , et al . Initial impact of a systematic multidisciplinary approach on the management of patients with gastroenteropancreatic neuroendocrine tumor [J ] . Endocrine , 2013 , 44 ( 2 ): 504 - 509 . DOI: 10.1007/s12020-013-9910-5 http://doi.org/10.1007/s12020-013-9910-5 http://link.springer.com/10.1007/s12020-013-9910-5 http://link.springer.com/10.1007/s12020-013-9910-5

浏览量

4443

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

中国抗癌协会乳腺癌诊治指南与规范（2026年版）

中国抗癌协会神经内分泌肿瘤诊治指南（2025年版）

中国抗癌协会乳腺癌诊治指南与规范（2024年版）

中国抗癌协会多原发和不明原发肿瘤诊治指南（2023年版）

甲状腺癌骨转移的诊治现状及展望